{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:18:01Z","timestamp":1792027081995,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["MOH-000527-00 (CIRG19nov-0006)"],"award-info":[{"award-number":["MOH-000527-00 (CIRG19nov-0006)"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCIS Centre Grant Seed Funding","award":["NMRC\/CG\/CG21Apr1005"],"award-info":[{"award-number":["NMRC\/CG\/CG21Apr1005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04297-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:19:15Z","timestamp":1775657955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Methylome profiling reveals context-dependent chemo-resistance mechanisms and enhances risk stratification in AML"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keir Audrey Mendoza","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Xin-Ning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa G.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak Ling","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Hin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameelah S.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"4297_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4297_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, Dohner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11\u201320.","journal-title":"Blood"},{"issue":"2","key":"4297_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41375-020-01110-3","volume":"35","author":"RB Walter","year":"2021","unstructured":"Walter RB, Appelbaum FR, Estey EH. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Leukemia. 2021;35(2):295\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"4297_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12935-024-03368-4","volume":"24","author":"N Kim","year":"2024","unstructured":"Kim N, Hahn S, Choi YJ, Cho H, Chung H, Jang JE, et al. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int. 2024;24(1):174.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4297_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","volume":"37","author":"K Mrozek","year":"2023","unstructured":"Mrozek K, Kohlschmidt J, Blachly JS, Nicolet D, Carroll AJ, Archer KJ, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37(4):788\u201398.","journal-title":"Leukemia"},{"issue":"17","key":"4297_CR6","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7(17):5122\u201331.","journal-title":"Blood Adv"},{"issue":"15","key":"4297_CR7","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/bloodadvances.2025015797","volume":"9","author":"NG Van Der Maas","year":"2025","unstructured":"Van Der Maas NG, Breems DA, Klerk CPW, Pabst T, Gradowska P, Thomas A, et al. A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse. Blood Adv. 2025;9(15):3853\u201364.","journal-title":"Blood Adv"},{"issue":"15","key":"4297_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood-2016-09-687822","volume":"129","author":"R Avellino","year":"2017","unstructured":"Avellino R, Delwel R. Expression and regulation of C\/EBPalpha in normal myelopoiesis and in malignant transformation. Blood. 2017;129(15):2083\u201391.","journal-title":"Blood"},{"issue":"14","key":"4297_CR9","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"WC Chou","year":"2011","unstructured":"Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803\u201310.","journal-title":"Blood"},{"issue":"1","key":"4297_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","volume":"23","author":"M Numata","year":"2023","unstructured":"Numata M, Haginoya N, Shiroishi M, Hirata T, Sato-Otsubo A, Yoshikawa K, et al. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023;23(1):36.","journal-title":"Cancer Cell Int"},{"key":"4297_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0807-0","volume":"19","author":"S Salehzadeh","year":"2019","unstructured":"Salehzadeh S, Guerrini F, Pizzano U, Grassi S, Ciabatti E, Iovino L, et al. The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. Cancer Cell Int. 2019;19:83.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"4297_CR12","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1182\/blood-2005-05-2168","volume":"106","author":"RG Verhaak","year":"2005","unstructured":"Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747\u201354.","journal-title":"Blood"},{"issue":"17","key":"4297_CR13","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1182\/blood-2008-05-156422","volume":"113","author":"J Zhou","year":"2009","unstructured":"Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052\u201362.","journal-title":"Blood"},{"issue":"25","key":"4297_CR14","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"4297_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13\u201327.","journal-title":"Cancer Cell"},{"key":"4297_CR16","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2019-130047","volume":"134","author":"S Vosberg","year":"2019","unstructured":"Vosberg S, Kerbs P, Jurinovic V, Metzeler K, Amler S, Sauerland C, et al. DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome. Blood. 2019;134:2715.","journal-title":"Blood"},{"key":"4297_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/genes12060895","author":"O Krali","year":"2021","unstructured":"Krali O, Palle J, B\u00e4cklin CL, Abrahamsson J, Nor\u00e9n-Nystr\u00f6m U, Hasle H, et al. DNA methylation signatures predict cytogenetic subtype and outcome in pediatric acute myeloid leukemia (AML). Genes. 2021. https:\/\/doi.org\/10.3390\/genes12060895.","journal-title":"Genes"},{"issue":"5","key":"4297_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1101\/gr.269233.120","volume":"31","author":"B Giacopelli","year":"2021","unstructured":"Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, et al. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Res. 2021;31(5):747\u201361.","journal-title":"Genome Res"},{"issue":"12","key":"4297_CR19","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","volume":"32","author":"H Dohner","year":"2018","unstructured":"Dohner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"4297_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13148-023-01474-0","volume":"15","author":"X Xu","year":"2023","unstructured":"Xu X, Wang H, Han H, Yao Y, Li X, Qi J, et al. Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia. Clin Epigenetics. 2023;15(1):54.","journal-title":"Clin Epigenetics"},{"key":"4297_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649267","volume":"12","author":"TH Hsiao","year":"2021","unstructured":"Hsiao TH, Wang RC, Lu TJ, Shih CH, Su YC, Tsai JR, et al. Chemoresponse of de novo Acute Myeloid Leukemia to \u201c7+3\u201d Induction can Be Predicted by c-Myc-facilitated Cytogenetics. Front Pharmacol. 2021;12:649267.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4297_CR22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","volume":"18","author":"LC Li","year":"2002","unstructured":"Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427\u201331.","journal-title":"Bioinformatics"},{"issue":"1","key":"4297_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-023-01767-1","volume":"22","author":"J Zhou","year":"2023","unstructured":"Zhou J, Toh SH-M, Tan TK, Balan K, Lim JQ, Tan TZ, et al. Super-enhancer-driven TOX2 mediates oncogenesis in natural killer\/T cell lymphoma. Mol Cancer. 2023;22(1):69.","journal-title":"Mol Cancer"},{"issue":"1","key":"4297_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.leu.2404960","volume":"22","author":"J Zhou","year":"2008","unstructured":"Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 2008;22(1):138\u201346.","journal-title":"Leukemia"},{"issue":"5159","key":"4297_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.8171323","volume":"264","author":"PD Crowe","year":"1994","unstructured":"Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, et al. A Lymphotoxin-\u03b2-Specific Receptor. Science. 1994;264(5159):707\u201310.","journal-title":"Science"},{"issue":"6","key":"4297_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jaci.2011.12.1003","volume":"129","author":"RW Saltzman","year":"2012","unstructured":"Saltzman RW, Monaco-Shawver L, Zhang K, Sullivan KE, Filipovich AH, Orange JS. Novel mutation in STXBP2 prevents IL-2-induced natural killer cell cytotoxicity. J Allergy Clin Immunol. 2012;129(6):1666\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"4297_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.14348\/molcells.2020.0124","volume":"43","author":"I Park","year":"2020","unstructured":"Park I, Son M, Ahn E, Kim Y-W, Kong Y-Y, Yun Y. The Transmembrane Adaptor Protein LIME Is Essential for Chemokine-Mediated Migration of Effector T Cells to Inflammatiory Sites. Mol Cells. 2020;43(11):921\u201334.","journal-title":"Mol Cells"},{"issue":"2","key":"4297_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12088","volume":"26","author":"X Xiong","year":"2023","unstructured":"Xiong X, Jian G. E2F1\u2011mediated RAB34 upregulation accelerates the proliferation and inhibits the cell cycle arrest and apoptosis of acute myeloid leukemia cells. Exp Ther Med. 2023;26(2):389.","journal-title":"Exp Ther Med"},{"issue":"1","key":"4297_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26093-2","volume":"12","author":"M Tulstrup","year":"2021","unstructured":"Tulstrup M, Soerensen M, Hansen JW, Gillberg L, Needhamsen M, Kaastrup K, et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nat Commun. 2021;12(1):6061.","journal-title":"Nat Commun"},{"issue":"19","key":"4297_CR30","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1182\/blood.2020006389","volume":"137","author":"B Estevez","year":"2021","unstructured":"Estevez B, Borst S, Jarocha D, Sudunagunta V, Gonzalez M, Garifallou J, et al. RUNX-1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells. Blood. 2021;137(19):2662\u201375.","journal-title":"Blood"},{"issue":"2","key":"4297_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41588-021-00993-x","volume":"54","author":"H Yang","year":"2022","unstructured":"Yang H, Zhang H, Luan Y, Liu T, Yang W, Roberts KG, et al. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat Genet. 2022;54(2):170\u20139.","journal-title":"Nat Genet"},{"issue":"8","key":"4297_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850-64.e9.","journal-title":"Cancer Cell"},{"issue":"47","key":"4297_CR33","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369\u201375.","journal-title":"Oncogene"},{"issue":"1","key":"4297_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2020.257964","volume":"107","author":"A Damnernsawad","year":"2022","unstructured":"Damnernsawad A, Bottomly D, Kurtz SE, Eide CA, McWeeney SK, Tyner JW, et al. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia. Haematologica. 2022;107(1):77\u201385.","journal-title":"Haematologica"},{"issue":"4","key":"4297_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.16253","volume":"189","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Li Y, Cheng J, Ma J, Li Q, Pang T. Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells. Br J Haematol. 2020;189(4):694\u2013706.","journal-title":"Br J Haematol"},{"issue":"3","key":"4297_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","volume":"73","author":"TM Penning","year":"2021","unstructured":"Penning TM, Jonnalagadda S, Trippier PC, Rizner TL. Aldo-Keto Reductases and cancer drug resistance. Pharmacol Rev. 2021;73(3):1150\u201371.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"4297_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/nbt1010-1045","volume":"28","author":"BE Bernstein","year":"2010","unstructured":"Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010;28(10):1045\u20138.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"4297_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1101\/gr.131169.111","volume":"22","author":"H Easwaran","year":"2012","unstructured":"Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, et al. A DNA hypermethylation module for the stem\/progenitor cell signature of cancer. Genome Res. 2012;22(5):837\u201349.","journal-title":"Genome Res"},{"issue":"8","key":"4297_CR39","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/2159-8290.CD-16-1032","volume":"7","author":"JL Glass","year":"2017","unstructured":"Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, et al. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discov. 2017;7(8):868\u201383.","journal-title":"Cancer Discov"},{"issue":"9","key":"4297_CR40","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1182\/blood-2015-09-668632","volume":"127","author":"S Uttarkar","year":"2016","unstructured":"Uttarkar S, Dasse E, Coulibaly A, Steinmann S, Jakobs A, Schomburg C, et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb\/p300 interaction. Blood. 2016;127(9):1173\u201382.","journal-title":"Blood"},{"issue":"2","key":"4297_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/blood-2012-01-403139","volume":"120","author":"M Cai","year":"2012","unstructured":"Cai M, Langer EM, Gill JG, Satpathy AT, Albring JC, Kc W, et al. Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation. Blood. 2012;120(2):335\u201346.","journal-title":"Blood"},{"issue":"22","key":"4297_CR42","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1002\/cncr.34481","volume":"128","author":"R Jia","year":"2022","unstructured":"Jia R, Ji M, Li G, Xia Y, Guo S, Li P, et al. Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy. Cancer. 2022;128(22):3929\u201342.","journal-title":"Cancer"},{"issue":"1","key":"4297_CR43","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27\u201342.","journal-title":"Nat Cancer"},{"issue":"10","key":"4297_CR44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer. 2024;24(10):694\u2013717.","journal-title":"Nat Rev Cancer"},{"key":"4297_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0463.","journal-title":"Sci Transl Med"},{"issue":"8","key":"4297_CR46","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","volume":"33","author":"NA McNeer","year":"2019","unstructured":"McNeer NA, Philip J, Geiger H, Ries RE, Lavall\u00e9e VP, Walsh M, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33(8):1934\u201343.","journal-title":"Leukemia"},{"issue":"23","key":"4297_CR47","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"key":"4297_CR48","doi-asserted-by":"publisher","first-page":"1274634","DOI":"10.3389\/fimmu.2023.1274634","volume":"14","author":"AM Massimino","year":"2023","unstructured":"Massimino AM, Colella FE, Bottazzi B, Inforzato A. Structural insights into the biological functions of the long pentraxin PTX3. Front Immunol. 2023;14:1274634.","journal-title":"Front Immunol"},{"issue":"10","key":"4297_CR49","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ng.3646","volume":"48","author":"MR Corces","year":"2016","unstructured":"Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet. 2016;48(10):1193\u2013203.","journal-title":"Nat Genet"},{"issue":"5","key":"4297_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrg.2016.13","volume":"17","author":"AP Feinberg","year":"2016","unstructured":"Feinberg AP, Koldobskiy MA, G\u00f6nd\u00f6r A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284\u201399.","journal-title":"Nat Rev Genet"},{"issue":"22","key":"4297_CR51","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681\u20139.","journal-title":"Blood Adv"},{"key":"4297_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/1471-2105-9-319","volume":"9","author":"A Statnikov","year":"2008","unstructured":"Statnikov A, Wang L, Aliferis CF. A comprehensive comparison of random forests and support vector machines for microarray-based cancer classification. BMC Bioinformatics. 2008;9:319.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"4297_CR53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2025;100(2):260\u201371.","journal-title":"Am J Hematol"},{"issue":"1","key":"4297_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14(1):163.","journal-title":"Blood Cancer J"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04297-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04297-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04297-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:04:05Z","timestamp":1781222645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04297-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4297"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04297-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study with patient tumor samples was approved by the ethics review board of National Cancer Institute of Singapore and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consents were obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors give consent for the publication of manuscript in\n                      Cancer Cell International\n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}